Breast cancer

Adjuvant systemic treatment of luminal A/B early breast cancer

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Educational Objective: Gain insight into the selection of adjuvant systemic therapy in premenopausal and postmenopausal patients with hormone receptor (HR)-positive HER2-negative early breast cancer.
Specialty: Medical oncology, Clinical oncology, Obstetrics & Gynaecology, (Surgical Oncology), (Radiation oncology)
Target Audience: CME (basic, intermediate), Residents (senior)
Latest update: January 2022
Background:

Adjuvant (postoperative) endocrine therapy is a major treatment strategy for HR-positive, HER2-negative early breast cancer. Questions remain: which type? Optimal duration? Should chemotherapy be added?

Tumours are grouped into surrogate intrinsic subtypes based on routine histology and immunohistochemistry data [1]. In this course, only patients with luminal A and luminal B and HER2-negative disease are included.

  1. Cardoso F, Kyriakides S, Ohno S, et al. Ann Oncol 2019;30:1194-220. PubMed